Search This Blog

Saturday, September 15, 2018

What You Need To Know About Medicare For All, Part II


  1. The real cost of Medicare includes hidden costs imposed on doctors and taxpayers.
Blahous estimates that the administrative cost of private insurance is 13%, more than twice the 6% it costs to administer Medicare. Single-payer advocates often use this type of comparison to argue that universal Medicare would reduce health care costs. But this estimate ignores the hidden costs Medicare shifts to the providers of care, including the enormous amount of paperwork that is required in order to get paid.
Medicare is the vehicle by which the federal government has been trying to force the entire health care system to adopt electronic medical records – a costly change that appears to have done nothing to increase quality or reduce costs, while making it easier for doctors to “up code” and bill the government for more money.
There are also the social costs of collecting taxes to fund Medicare, including the costs of preparation and filing and the costs of avoiding and evading taxation. By some estimates, the social cost of collecting a dollar of taxes can be as high as 25 cents.


Milliman & Robertson study estimates that when all these costs are included Medicare and Medicaid spend two-thirds more on administration than private insurance spends.
Single payer advocates are also fond of comparing the administrative costs of health care in the United States and Canada – again claiming there is a potential for large savings. But these comparisons invariably include the cost of private insurance premium collection (advertising, agents’ fees, etc.), while ignoring the cost of tax collection to pay for public insurance. Using the most conservative estimate of the social cost of collecting taxes, economist Benjamin Zycher calculates that the excess burden of a universal Medicare program would be twice as high as the administrative costs of universal private coverage.
  1. Not a single problem in Obamacare would go away under Medicare for all.
If everyone could join Medicare, what premium would they have to pay? Would the premiums be actuarially fair, representing the expected cost of the enrollee’s heath care? Or would there be subsidies and cross subsidies as there are under Obamacare? Would the premium vary by age? By income? By health status? By healthy living choices?
What about the role of employers? Obamacare tried to force them to pay a large part of the cost of reform by imposing a mandate and requiring them to cover a liberal set of benefits.  Economists tell us that employee benefits are substitutes for wages and are therefore “paid for” by the employees. But on paper, employers write checks for about 75% of the cost of insurance for about 95% of the people who have private insurance. Under Medicare for all, would they get off scot free?
Then there is the exchange. Medicare has one. It’s how roughly one-third of seniors get into Medicare Advantage plans. Like the Obamacare exchanges, the Medicare Advantage exchange has government subsidies for private insurance, mandated benefits, annual open enrollment and no discrimination based on health status. And, it seems to work reasonably well.
The Obamacare exchanges, by contrast, have been a disaster – with spiraling premiums, unconscionably high deductibles, extra charges for chronic patients who need specialty drugs, and a race to the bottom on provider networks that exclude more and more of the best doctors and the best hospitals.
What will happen when the same politicians, catering to the same interest groups that gave us Obamacare, set out to design an exchange for their Medicare-for-all program? That’s anyone’s guess.
But if Democrats know how to defy the special interests and create a workable exchange, wouldn’t they have done that already in the market for individual insurance?
  1. Medicare is already on a path to health care rationing.
Medicare is already on an unsustainable path. It has made future promises that far exceed expected revenues, based on the Medicare payroll tax and Medicare’s share of general federal revenues. Ironically, Democrats, rather than Republicans, were the first to formally acknowledge this fact. At the time Congress passed the Affordable Care Act (ACA) creating Obamacare, the Medicare trustees estimated the unfunded liability in the program at $89 trillion – stretching out indefinitely into the future. Yet, in the next trustees’ report that figure had dropped to $37 trillion.
Think about that. When Barack Obama signed the ACA into law, he wiped away $52 trillion of federal government debt. How did that happen? By theoretically putting the government’s health care spending on a budget.
For the past 40 years real, per capita health care spending has been growing at twice the rate of growth of real per capita income. That’s not only true in this country; it is about the average for the whole developed world. You don’t need to be an accountant or a mathematician to know that if an expenditure item is growing at twice the rate of growth of your income, it will crowd out more and more of other spending – eventually taking up the entire pie.
To deal with this problem, there are three “global budgets” that Obamacare promised to restrict three budgets to a rate of growth no greater than the rate of real GDP growth per capita plus about ½ of a percent . These budgets are total Medicare spending, Medicaid hospital spending and (after 2018) federal tax subsidies in the health insurance exchanges.
If these budgets are binding, the burden of excess growth in health care spending for the federal government will have been relieved – forever.
But here is the problem. The Obama administration only “solved” the problem with pen and ink. It didn’t give the private sector any new tools to control costs. It didn’t empower doctors or hospitals to practice medicine in a more efficient way.
There was an enforcement mechanism: An Independent Payment Advisory Board (IPAB), tasked with the job of keeping spending below the cap – mainly by recommending reductions in fees to doctors and hospitals. In a bipartisan budget deal this year, Republicans in Congress abolished IPAB. But in their latest report, the Medicare trustees imply they believe future administrations will still have the power to enforce the spending cap.
That means that Medicare fees to providers will fall progressively behind private sector fees through time. And that means one of two things must happen. Either providers will respond to lower fees by providing less care to seniors or they will shift costs to non-seniors in the form of higher fees, higher insurance premiums and higher state and local taxes.
One way providers could cut costs is by providing fewer amenities. Hospital patients could be in wards with, say, 4 or 6 beds instead of single-room occupancy – the way hospitals used to be configured in this country and the way they still are in some other countries. Hospital food could be meals-ready-to-eat (what combat soldiers take into the field) rather than the fancy cuisine some facilities serve up today.
Another way to cut costs is to deny seniors access to the most expensive care. Writing in Health Affairs soon after the passage of the ACA,  Harvard health economist Joe Newhouse noted that many Medicaid enrollees are forced to seek care at community health centers and safety net hospitals because Medicaid payment rates are so low. He speculated that senior citizens may eventually face the same plight under Obamacare.
A third way to cut costs is rationing by waiting. It is already common practice for doctors to prioritize – seeing private-pay patients first, Medicare patients next and Medicaid patients last. As in other countries with rationing problems, those at the end of the line may never get seen.
But if everyone were in Medicare, wouldn’t seniors be on equal footing with non-seniors? Since there would be no more cost shifting (no private patients to shift costs to) the entire burden of spending cuts would fall on Medicare patients themselves. Yet everyone in the medical world knows that older patients have more difficult problems and take more time. That observation wouldn’t be lost on practitioners in a system in which time is money and the payment for time keeps getting smaller and smaller. Seniors would be less favored patients – just because they are seniors.
However they are made, the future cuts in spending will be large. Writing at the Health Affairs Blogformer Medicare trustee Thomas Saving and I proposed several ways of thinking about what Medicare’s global budget will mean for seniors.  One way to think about these changes is to compare them to the average amount Medicare was spending on enrollees prior to Obamacare. For 65-year-olds, the forecasted reduction in spending is roughly equal to three years of average Medicare spending. For 55-year-olds, the loss expected is the rough equivalent of five years of benefits; and for 45-year-olds, it’s almost nine years.
Another way to think about the Medicare spending reductions is to compare them to an alternative reform that would have reduced spending by the same amount: increasing the age of eligibility.  The Medicare spending cuts called for under Obamacare are the rough equivalent of raising the age of eligibility for 65-year-olds from 65 to 68. They are the equivalent of making 55-year-olds wait until they reach age 70 and 45-year-olds wait all the way to age 74!
Remember, these are spending cuts already called for under current law. They will be much more severe if seniors have to compete with younger patients for their care.

Systematic Reform Needed to End Sexual Harassment in Medicine


To put an end to the high rate of harassment of women in medicine, the field must address systematic undervaluing of women and a culture that promotes a hostile work environment, according to a pair of editorials published online September 12 in the New England Journal of Medicine.
The #MeToo movement that has rocked many fields has begun to ripple through medicine, but some women in the field are skeptical that medicine is ready to tackle the systematic undervaluing of women in the field that they say contributes to harassment.
“When women are systematically devalued, promoted later than men, and paid less, this treatment undermines their institutional power and their ability to report or defend themselves against ongoing sexual abuse, particularly at the hands of male superiors, including those in control of their salaries, promotions, and opportunities,” write Esther Choo, MD, MPH, from the Center for Policy Research in Emergency Medicine at Oregon Health and Sciences University in Portland; Jan van Dis, MD, from the Ob Hospitalist Group in Burbank, California; and Dara Kass, MD, from the Department of Emergency Medicine at Columbia University Medical Center, New York City, in their editorial. “In this and other ways, persistent disparities in pay and career advancement are an integral part of the machinery that facilitates gender-based abuse of all kinds.”
report released by the National Academies of Science, Engineering, and Medicine in June highlighted that harassment of women is prevalent throughout the sciences, but is highest in medicine. The report cited studies that found up to half of female medical trainees report sexual harassment from faculty or staff.
The most common form of harassment documented in the report, and in medicine particularly, was gender harassment. This includes crude or sexist comments or other behavior that creates a hostile or unwelcoming environment for women. A separate survey by Medscape found that 12% of female physicians have experienced sexual abuse, harassment, or misconduct that was overtly sexual in nature, including unwanted communications of a sexual nature, unwanted physical contact, or sexual coercion.
A second editorial, written by National Academy of Medicine President Victor Dzau, MD, and Paula Johnson, MD, the president of Wellesley College and cochair of the committee that wrote the National Academies of Science, Engineering, and Medicine report, outlines the ways the culture of medicine and the organization of medical institutions contribute to harassment. For example, they note the report’s finding that hierarchical, male-dominated organizations with permissive cultures about harassment breed abuse. They note that although more women than men now enter medicine each year, men still disproportionately hold leadership positions, with women making up just 38% of faculty members, 15% of department chairs, and 16% of deans. They are also paid less, are promoted less, and are less likely to be honored by societies.
“Adding to the power differential is a culture that accepts some degree of suffering as a matter of course,” they write. Women who speak up about abuse face retaliation or being labeled a troublemaker. These cultural problems likely contribute to physician burnout, Dzau and Johnson note.
But unraveling systematic sexism and abuse in medicine will not be easy.
“If there is anything the report makes clear, however, it is that medicine is ill prepared to take meaningful steps toward actually ending harassment,” Choo and colleagues write. They note that it is easier for institutions to blame a few bad actors than to unravel institutional cultures that facilitate poor treatment of women.
“Correcting inequities in salary, career advancement, and leadership positions requires more global fixes than even those who are deeply committed to eradicating sexual harassment in the workplace may be willing to consider,” they explain. “Because these problems are inextricably linked, however, it may be that our lack of progress on any one of them is in fact rooted in our habit of addressing them one by one, in isolation.”
In fact, the National Academies of Science, Engineering, and Medicine has been criticized for failing to revoke membership from individuals who have been sanctioned for sexual harassment, retaliation, and assault. BethAnn McLaughlin, PhD, an assistant professor of neurology and pharmacology at Vanderbilt in Nashville, started a petition urging the academies to correct this; the petition has garnered more than 5000 signatures.
Choo and colleagues recommend the field adopt the same preventive approach they do for chronic diseases to sexism and harassment in medicine and not wait for “metastatic manifestations of harassment.”
“In this case, what began as a smoldering fire is now scorching the curtains and the roof, threatening the entire house of medicine,” they write, urging colleagues to support the movement to stop it or risk falling behind.
Choo reports receiving other support from Equity Quotient outside the submitted work and is president of the nonprofit Gender Equity Research Foundation, which supports research on the careers of women in medicine. Kass reports receiving personal fees from FeminEM.org outside the submitted work. The remaining authors have disclosed no relevant financial relationships.
N Engl J Med. Published online September 12, 2018. Choo full textDzau and Johnson full text

‘ADHD Boosts Risk of Early-Onset Parkinson’s, Other Diseases’


Having attention-deficit/hyperactivity disorder (ADHD) may raise the risk developing Parkinson’s disease (PD) and related disorders, results of a population-based study suggest.
Investigators found that patients with ADHD were more than twice as likely to develop early-onset Parkinson’s and PD-related disorders relative to matched individuals who did not have ADHD. The risk was sixfold to eightfold higher in ADHD patients prescribed stimulant medications.
“This link between ADHD and its treatment with psychostimulants and Parkinson’s disease–like disorders (PDLDs) has not been shown before,” senior author Glen Hanson, PhD, professor of pharmacology and toxicology, University of Utah, Salt Lake City, told Medscape Medical News.
“That there is a link between pediatric mental health problems (eg, ADHD) and their treatment (eg, stimulants) and neurodegenerative diseases (eg, PDLDs) that typically express in older, and even geriatric, populations is a relatively new and somewhat disturbing concept,” said Hanson.
The study was published online September 12 in Neuropsychopharmacology.

Side Effect of Stimulants?

The investigators examined associations between ADHD and PD and related disorders using the Utah Population Database (UPDB).
They created a cohort of 31,769 individuals who had a history of ADHD, of whom 4960 were treated with stimulant medications, and a non-ADHD comparison cohort of 158,790 individuals matched (5:1) for sex and age.
None of the participants had a prior diagnosis of PD or related disorders of the basal ganglia and cerebellum or a history of substance abuse. All participants were at least 20 years old in 2011. The development of PD and related disorders was tracked until age 60 years.
In the ADHD cohort, the rate of incident PD and related diseases was 0.52%, compared with 0.19% in the non-ADHD cohort. The median age at disease onset was slightly younger in the ADHD than the non-ADHD cohort (43 years vs 45 years).
Overall, ADHD was associated with a 2.4-fold increased risk for PD and related diseases (adjusted hazard ratio [aHR], 2.4; 95% confidence interval [CI], 2.0 – 3.0; P < .0001), the research team found.
The risk was significantly higher in ADHD patients who took stimulants (aHR, 6.0; 95% CI, 3.9 to 9.1; P < .0001) than it was for those who had not taken stimulants (aHR, 1.8; 95% CI, 1.4 – 2.3; P < .0001).
ADHD patients who were only prescribed methylphenidate had an eightfold increased risk for PD and related diseases compared to persons who did not have ADHD (aHR, 8.0; 95% CI, 4.2 – 15.1; P < .0001).
In their article, the researchers caution that it may be that the apparent association between being prescribed stimulant medication and being at higher risk for PD and related diseases is a result of the fact that the phenotype of patients who are prescribed stimulant medication is more severe than that of persons who are not prescribed a stimulant, rather than a direct association between prescribed stimulant use and these diseases.
“The jury is still out. The increased risk we observed in people could be linked to having ADHD itself or perhaps a more severe form of ADHD, which may be more likely to be treated with medications,” first author Karen Curtin, PhD, from the University of Utah, said in a news release.
She also noted that the absolute risk of developing PD remained low. “If we were to follow 100,000 adults prescribed treatment for ADHD over time, we estimate that over a year, eight to nine patients will develop Parkinson’s disease before age 50,” she noted. By comparison, in a population of 100,000 persons who did not have ADHD, one to two would develop PD.
Prior studies provide some support for their findings. Preclinical studies have shown that exposure to high doses of amphetamine or its analogue, methamphetamine, causes persistent basal ganglia dopaminergic deficits. In clinical studies, basal ganglia dopaminergic deficits have been found in people who have a history of methamphetamine abuse, which is of “particular interest,” given epidemiologic reports that people who abuse amphetamine/methamphetamine are more likely to develop PD, the researchers say.
In addition, in a prior study using the UPDB, they found that individuals with a history of amphetamine/methamphetamine abuse were two to three times more likely to develop PD or related disorders.

More Study Needed

The researchers note the current results should be considered preliminary. One limitation of the study is that it is possible that persons may have been misclassified as not having ADHD. Such misclassification could have occurred as a result of individuals being diagnosed with the disorder in a state other than Utah, or as a result of missed or incorrect diagnosis of PD-like disease, or through the lack of information on the duration of use and dosage of ADHD medication prescribed, they point out.
Nonetheless, Hanson said the findings have several “important clinical implications.”
“First, our findings suggest that a significant fraction of patients who develop PDLD have a history of ADHD with stimulant treatment. Perhaps by studying this ADHD population we can discover some important causative factors for PDLDs that can lead to be treatment or even prevention,” he explained.
“Second, if it is determined that treatment of ADHD with the psychostimulants is responsible for the substantial increase in PDLD expression in ADHD patients (going from a 2.3-fold to an 8.6-fold increase), it would be very important to find other drugs to treat ADHD that do not have this side effect,” he said.
“Finally, while our findings absolutely do not mean that ADHD patients should no longer be treated with the stimulant drugs if needed, hopefully it would be considered in the benefit/risk discussion for deciding the best approach for managing these persons,” said Hanson.
The study was supported by the Huntsman Cancer Foundation. The UPDB is supported by the University of Utah ‘ s Program in Personalized Health and the Center for Clinical and Translational Science. The authors have disclosed no relevant financial relationships.
Neuropsychopharmacol. Published online September 12, 2018. Abstract

Cancer Incidence Continues to Rise: 1 in 5 Men, 1 in 6 Women


In 2018, an estimated 18.1 million new cases cancer will be diagnosed globally, and 9.6 million will die from the disease, according to the latest report from the International Agency for Research on Cancer (IARC).
One in 5 men and one in 6 women worldwide will develop cancer during their lifetime, and one in 8 men and one in 11 women will die from cancer.
Cancer incidence and mortality are rapidly growing worldwide, the report notes.
“The increasing cancer burden is due to several factors, including population growth and ageing as well as the changing prevalence of certain causes of cancer linked to social and economic development,” the IARC commented in a statement. “This is particularly true in rapidly growing economies, where a shift is observed from cancers related to poverty and infections to cancers associated with lifestyles more typical of industrialized countries.”
Worldwide, the total number of people who are alive within 5 years of a cancer diagnosis (the 5-year prevalence) is estimated to be 43.8 million.
The GLOBOCAN 2018 database is part of the IARC Global Cancer Observatory. It provides estimates of incidence and mortality for 36 types of cancer in 185 countries, as well as for all cancer sites combined.
An analysis of these results was published online September 12 in CA: A Cancer Journal for Clinicians.
“These new figures highlight that much remains to be done to address the alarming rise in the cancer burden globally and that prevention has a key role to play,” commented IARC Director Christopher Wild, MD, in a statement. “Efficient prevention and early detection policies must be implemented urgently to complement treatments in order to control this devastating disease across the world.”

Global Patterns

GLOBOCAN 2018 estimates that almost half of all cases and over one half of related deaths will occur in Asia, partly because almost 60% of the global population resides on that continent. Europe accounts for almost a quarter (23.4%) of the total number of global cases and about a fifth (20.3%) of cancer-related mortality, but it comprises only 9% of the world population. The Americas account for 13.3% of the global population, with 21% of cancer incidence and 14.4% of related mortality.
Conversely, cancer deaths in Asia (57.3%) and Africa (7.3%) are much higher than the incidence (48.4% and 5.8%, respectively) in those regions, largely because of the distribution of cancer types and higher case fatality rates.
The incidence rate for all cancers combined was about 20% higher in men (age‐standardized rate [ASR], 218.6 per 100,000 person-years) than in women (ASR, 182.6 per 100,000), although there was substantial variation across regions.
For men, there was an almost sixfold difference, from 571.2 per 100,000 in Australia/New Zealand to 95.6 per 100,000 in Western Africa. Similar ranges were seen for women, with a nearly fourfold difference, from 362 per 100,000 in Australia/New Zealand to 96.2 per 100,000 in South‐Central Asia.

Lack of blood cancer awareness in China and Japan – Janssen report


Janssen has published a report revealing significant gaps in understanding of blood cancer in individuals in China and Japan, calling for action to improve awareness about the disease in the region.
The Make Blood Cancer Visible (MBCV) Asia Pacific report marked the beginning of an effort across the region to build awareness and support for those living with blood cancers such as lymphoma, leukaemia, and myeloma.
The report featured an independent survey of 3,000 individuals in China and Japan, and was conducted by YouGov and Nielsen.
Findings showed in both China and Japan, roughly half of people surveyed could not name a single symptom of blood cancer.
In Japan, only 1% of people surveyed recall hearing or reading anything about blood cancer in the last year.
And in China, four in 10 people surveyed wrongly believed blood cancer is contagious, or don’t know if it is contagious.
While low awareness could pose a significant obstacle to national efforts in prevention and early diagnosis, the survey also highlights that a large proportion of respondents want more information about prevention, treatment options and patient experiences.
The MBCV Asia Pacific survey asked 1,000 representatives of the general population in Japan and 2,000 representatives of the general population in China 15 questions about their general awareness and perceptions of blood cancer.
All questions had fixed answer categories and were online, self-administered surveys. To ensure anonymity, all respondents were assigned an anonymous alphanumeric identification to protect their identity. The study was conducted from 1 February 2018 to 8 February 2018 in both countries.
To shed light on the patient experience in Asia Pacific, the report also showcases a collection of thirteen blood cancer patient stories from across the region. They reveale that even at the time of diagnosis, many survivors were unable to identify a single symptom until their disease had progressed significantly.
The report was developed with the help of the blood cancer support organisation, The Max Foundation.
Mei Ching Ong
Mei Ching Ong, regional head for Asia Pacific at The Max Foundation, said: “Upon reading through the perceptions around blood cancer in China and Japan, I am reminded of how much work there is to do, not just in these countries but across the region.”

NVIDIA unveils next-gen medical imaging tech


Technology firm NVIDIA has unveiled its latest development in supercomputing, which will expand the way artificial intelligence (AI) is used in healthcare and medical imaging.
The company’s Clara platform combines hardware and software in AI applications that can be used for the early detection, diagnosis and treatment of diseases.
Clara allows the medical AI industry to “build and deploy breakthrough algorithms to create intelligent instruments and automate healthcare workflows.”
Unlike traditional computing, NVIDIA uses GPU (graphics processing unit) computing as opposed to that run via a CPU (central processing unit). GPUs allow vast amounts of information to be processed repeatedly, swiftly and efficiently.
One major advantage of this latest development is that the Clara platform will allow immense amounts of medical data to be generated each second, which will be valuable to those making diagnoses and who are working in pharma R&D.
Such rapid advances in AI are already helping start-ups in the field to make leaps when it comes to what they can achieve – and how quickly.
For instance, Subtle Medical uses AI to reduce the costs associated with imaging, by cutting down the time needed – as well as the amount of time patients spend inside PET and MRI scanners.
Through deep learning, Subtle Medical’s researchers have improved image quality, which means scans are faster and more accurate. MRI applications acquire images in one-quarter of the usual time and use only one-tenth of the contrast dosage, gadolinium, a potentially harmful metal, which is deposited in the body during MRI contrast scans. Research into the effects of gadolinium is ongoing.
Enhao Gong, founder of Subtle Medical, said, “We are using AI to improve workflow for MRI and PET exams. NVIDIA’s Clara platform will enable us to seamlessly scale our technology to reduce risks from contrast and radiation, taking imaging efficiency and safety to the next level.”
Fujifilm is also using NVIDIA’s DGX-2 supercomputer to speed up its AI-based R&D healthcare projects. The company works in pharma, biologic contract development and manufacturing organisation (CDMOs), regenerative medicine and medical equipment, including imaging.
Masataka Osaki, Japan country manager and vice president of worldwide field operations at NVIDIA, said, “Improving the accuracy and delivery of medical care is one of society’s greatest challenges.
“Combining Fujifilm’s expertise in medical imaging systems with NVIDIA’s AI leadership will supercharge the development and deployment of breakthrough applications for intelligent medical imaging systems.”

Thermo Fisher Scientific expands bioprocessing with BD acquisition


Thermo Fisher Scientific announced the acquisition of BDs Advanced Bioprocessing unit, which will join its Life Sciences Solution business.
In its latest investment into the biomanufacturing space, Thermo Fisher moved to acquire Beckon, Dickinson and Companys portfolio in the area, which includes peptones that improve cell culture media formulations.
The Advanced Bioprocessing unit has an approximate annual revenue of $100m(86.25m). It is built to provide services that improve cell culture yield while reducing variability.
A spokesperson for Thermo Fisher told us that these services will be complementary to our existing offering[s] and will add strong technical service programs.
A spokesperson for Thermo Fisher stated that the talent and expertise of the Advanced Bioprocessing teamis a key reason we are interested in acquiring the business; However, they did not confirm the numbers of staff that would be retained, stating only that such plans are just being formed.
The acquisition is expected to be completed in early 2019, for an undisclosed fee, and will add to a number of deals Thermo Fisher has made within bioprocessing as of late.
Earlier this year, the company spent $50m to bolster capacity at its St. Louis, Missouri, facility and signed a long-term contract with Juno Therapeutics to develop CAR T therapies.